Isodiol Phytoceutical Division

Isodiol International Inc., a global Bioactive Phytoceutical innovator, specializing in the development of pharmaceutical and wellness products, announces further to its introduction of the Phytoceutical division on September 5, 2017, the launch of the market’s first non-cannabis, Highly bioactive cannabinoid, CBD, derived from the Hops plant. The Cannabinoids are derived using proprietary genetics and extraction technology that will allow for the isolation of the cannabinoids and terpenes without denaturing the molecule.

Sourcing natural, highly bioactive cannabinoids to supplement the endocannabinoid system in the human body is the key to developing targeted healthcare remedies. Hops derived cannabinoid products have shown a very favorable response and promising results in independent clinical studies for various diseases. The company will continue to collaborate with universities and alternative health facilities in the US and overseas to validate the science.

Phytoceutical is plant-based medicinal remedies. Most pharmaceutical drugs are synthetic versions of plant compounds.

The Isodiol focus on Bioactive CBD makes remarkable sense because the human body accepts plants as “natural.” It rejects synthetic drugs as a “xenobiotic” or “foreign substance.”

Our study beginning with BioActivity of 2-(6-isopropenyl-3-methyl-2-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol through measurement and research.

2-(6-isopropenyl-3-methyl-2-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol is a fantastic molecule which bridges the human central nervous system (CNS) and immune system.

2-(6-isopropenyl-3-methyl-2-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol maintains “homeostasis” of our immune system and our biochemical pathways.

Its natural “bioactive” affinity for the human CB2 receptor is rapidly degraded if it is from an inactive source or if it is improperly processed.

Every year, more than 2 million Americans suffer from serious pharmaceutical drug reactions.

The Company anticipates products will be ready for distribution within the next four weeks.